Sirnaomics Ltd. · HKEX:2257
Sirnaomics — Investor Presentation (2023)
20 slides from Sirnaomics's investor presentation, 2023
Slide 1: Meeting with investors – STP705 Fat Remodeling interim results
Sirnaomics Ltd. (2257.HK) Meeting with investors – STP705 Fat Remodeling interim results 0
Slide 2: Disclaimer
Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by representatives of Sirnaomics Ltd. (the “Company”) for use in presentations by
Slide 3: Two Proprietary Delivery Platforms and Therapeutic Areas
Two Proprietary Delivery Platforms and Therapeutic Areas PNP Platform GalNAc Platform 1 2 (Clinical Stage) (Clinical Candidate) CPP GalAhead ™ siRNA PDoV-GalNAc ™ HKP and HKP(+H) are well suited for siRNA Therapeutics or mRNA Therapeutics and Vaccine Deliveries mRNA Cancer Fibrosis Diseases Viral In
Slide 4: Polypeptide Nanoparticle Platform for RNA Delivery
Polypeptide Nanoparticle Platform for RNA Delivery Backbone PNP delivery platform is a potential game changer Significant advantages against existing platforms siRNA is much more than for hepatocytes of the liver ✓ A wide range of organs targeted: Tumor cells, lung Brain cells, and non- hepatocyte l
Slide 5: Prioritized Product Pipeline Advancing Oncology Programs
Prioritized Product Pipeline Advancing Oncology Programs Delivery Pre- IND Phase Candidate Gene Targets Indications IND Phase I Phase II Rights Status Platform clinical Enabling III Communicating with Global isSCC FDA re late-stage trial Global Data readout in Q2 STP705 TGF-β1/COX-2 PNP-IT 2023, Com
Slide 6: Market Size of Submental Fat Reduction
Market Size of Submental Fat Reduction Global market increases from USD 3.5b in 2022 to USD 9.4b in 2030 Global market size of submental fat reduction treatment, 2022-2030 CAGR 2022-30E USD billion Total 13.2% Market size of non-invasive submental fat reduction 9.4 8.3 Market size of invasive submen
Slide 7: Market for Fat Reduction in Different Parts of Body
Market for Fat Reduction in Different Parts of Body Market potential for different parts of the body Source：Rabin Research Report(n.d.) interview of 1,076 US men and women. Retrieved from https://10xbio.com/wp-content/uploads/2019/05/10xBioNonConfidential51619.pdf 6
Slide 8: Interim Data from Phase I Clinical Trial of STP705 for Medical Aesthetic
Interim Data from Phase I Clinical Trial of STP705 for Medical Aesthetic 7
Slide 9: Unexpected Findings in a Clinical Trial of isSCC
Unexpected Findings in a Clinical Trial of isSCC In the isSCC clinical phase 2a trial we found that at 120µg in the high dose group, narrowing of the subcutaneous fat layer and visible adipose tissue necrosis were observed Subject 1: Right forearm Subject 2: Right clavicle When the world gives you L
Slide 10: STP705 Fat Reduction in a Minipig Model Experiment
STP705 Fat Reduction in a Minipig Model Experiment Study Design Results ➢➢ 3STP705: repeat dose treatment, 1x weekly for 3 Tx 60ug, 120ug, 200ug Dosing: ➢ Single injection location ➢ N= 3 sites per dose group Mean Subcuticular Thickness (to Superficial Fascia) in µm ◼ Once weekly ➢ 8-weekfor three w
Slide 11: STP705 - Fat Remodeling Phase I
STP705 - Fat Remodeling Phase I Accidental discovery of subcutaneous fat reduction in the treatment of isSCC Preclinical: Minipig Model Efficacy Validation STP705 1 dose, Kybella 2 doses, after 56 days Control group Average thickness (um) Fat layer per group STP705 Treatment group Unrelated sequence
Slide 12: Innovative Dual-Targeted RNAi Therapeutics
Innovative Dual-Targeted RNAi Therapeutics Targeting both TGF-ß1 and COX-2 Selection of “Gate Keeper” Targets TGF-β1 COX-2 PGE2 TGF-βrII, TGF- βrI EP2 P Smad2 P Smad3 γ β 𝛼𝑠 PI3K Small independent pathways GSK- -P P P P P Axin AC Axin AKT 3β MAPK PI3K Smad2 Smad3 Smad2 Smad3 GSK3 Smad4 TIF1γ β-…
Slide 13: STP705 Fat Remodeling - Mechanism of Action
STP705 Fat Remodeling - Mechanism of Action TGFβ1 association with obesity COX- 2 association with obesity Recent findings on the role of TGFβ1/Smad3 signaling COX-2 is the key enzyme in eicosanoid metabolism in the pathogenesis of obesity and type 2 diabetes have that converts eicosanoids into a nu
Slide 14: STP705 Fat Remodeling - Protocol and Main Focus
STP705 Fat Remodeling - Protocol and Main Focus STP705 fat remodeling clinical Phase I in progress Clinical Protocol: To evaluate the safety and tolerability of STP705, delivered via subcutaneous injection. STP705 will be administered to 6 subjects on day 1, 28 and 56. Each subject will be treated w
Slide 15: STP705 Fat Remodeling - Histological Scoring
STP705 Fat Remodeling - Histological Scoring ▪ Study Design 7 Groups: (i) placebo; (ii) 120ug (0.5mL injection), (iii) 120ug (1.0mL injection), (iv) 240ug (0.5mL injection), (v) 240ug (1.0mL injection), (vi) 320ug (0.5mL injection), (vii) 320ug (1.0mL injection) ▪ N= 6 subjects; each subject receive
Slide 16: Adipose Tissue Comparison
Adipose Tissue Comparison Overall Severity Scoring 320 320 Data represents draft analysis using the interim analysis table. Full evaluation by a clinical/biostatistician expert needs to be conducted to verify these results. 15
Slide 17: Treatment vs Control Groups (Changes in Fat Layer)
Treatment vs Control Groups (Changes in Fat Layer) 320 320 Data represents draft analysis using the interim analysis table. Full evaluation by a clinical/biostatistician expert needs to be conducted to verify these results. 16
Slide 18: Full Speed Ahead - Future Milestones
Full Speed Ahead - Future Milestones isSCC late-stage KOL Advisory US FDA Pathway Confirmatory clinical trial arrangement Meeting Guidance Study Preparing Q2 2023 2023-2024 BCC late-stage KOL Advisory US FDA Pathway Confirmatory clinical trial STP705 arrangement Meeting Guidance Study Q3 2023 Q4 202
Slide 19: STP705/STP707 - Fat Reduction Mechanism of Action
STP705/STP707 - Fat Reduction Mechanism of Action 18
Slide 20: RNAi - Great Potential in Fat Remolding Area
RNAi - Great Potential in Fat Remolding Area Enhance and apply our proprietary delivery platforms to advance the development 01 of innovative therapeutic modalities for the treatment of a broad range of disease states and strengthen our intellectual property position Rapidly advance development of o